|
"hsu c"的相關文件
顯示項目 711-720 / 881 (共89頁)
<< < 67 68 69 70 71 72 73 74 75 76 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
Shao, Y-Y.; Chen, B-B.; Lin, Z-Z.; Hsu, C-H.; Wang, M-J.; Cheng, A-L.; Hsu, C.; 邵幼雲; 林宗哲; 鄭安理; 陳邦斌; 徐志宏; 許駿 |
| 臺大學術典藏 |
2016 |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
CHIH-HUNG HSU; Hsu C.; Guo J.-C.; Wu H.; Yang S.-H.;Kuo T.-C.;Wu H.;Guo J.-C.;Hsu C.;Chih-Hung Hsu;Tien Y.-W.;Yeh K.-H.;Cheng A.-L.;Kuo S.-H.; Yang S.-H.; Kuo T.-C.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 國家衛生研究院 |
2015-12 |
Towards an endpoint cell motility assay by a microfluidic platform
|
Yeh, C;Tai, W;Lin, C;Juang, D;Wu, C;Chen, Y;Hsu, C |
| 國家衛生研究院 |
2015-12 |
A decade of changes in preferences for life-sustaining treatments among terminally Ill patients with cancer
|
Tang, ST;Liu, TW;Wen, FH;Hsu, C;Chang, YH;Chang, CS;Sung, YC;Hsieh, CI;Chang, SY;Liu, LN;Chiang, MC |
| 國家衛生研究院 |
2015-11 |
Medical care and costs of patients with systemic lupus erythematosus in Taiwan
|
Cheng, J;Huang, C;Hsu, C |
| 國家衛生研究院 |
2015-09 |
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou, DL;Shyue, SK;Lin, LI;Feng, ZR;Liou, JY;Fan, HH;Lee, BS;Hsu, C;Cheng, AL |
| 國家衛生研究院 |
2015-07 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Park, JO;Oh, DY;Hsu, C;Chen, JS;Chen, LT;Orlando, M;Kim, JS;Lim, HY |
| 國立成功大學 |
2015-05-01 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, J. S.; Hsu, C.; Chiang, N. J.; Tsai, C. S.; Tsou, H. H.; Huang, S. F.; Bai, L. Y.; Chang, I. C.; Shiah, H. S.; Ho, C. L.; Yen, C. J.; Lee, K. D.; Chiu, C. F.; Rau, K. M.; Yu, M. S.; Yang, Y.; Hsieh, R. K.; Chang, J. Y.; Shan, Y. S.; Chao, Y.; Chen, L. T. |
| 國家衛生研究院 |
2015-05 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, JS;Hsu, C;Chiang, NJ;Tsai, CS;Tsou, HH;Huang, SF;Bai, LY;Chang, IC;Shiah, HS;Ho, CL;Yen, CJ;Lee, KD;Chiu, CF;Rau, KM;Yu, MS;Yang, Y;Hsieh, RK;Chang, JY;Shan, YS;Chao, Y;Chen, LT |
| 國家衛生研究院 |
2015-04 |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
Liang, PC;Ch'ang, HJ;Hsu, C;Chen, LT;Shih, TTF;Liu, TW |
顯示項目 711-720 / 881 (共89頁)
<< < 67 68 69 70 71 72 73 74 75 76 > >>
每頁顯示[10|25|50]項目
|
